English

Insight Molecular Diagnostics Inc.

EDGAR

IMDX Quarterly report (10-Q) · filed 2026-08-10

Annual consolidated revenue for 2025: about USD 4.055M, using the latest reported figures. The previous period, 2024, was about USD 1.881M.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

239 thousand USD

2026 Q2 · USD

Exact inputs and evidence

Revenue: 239000 USD Source

Operating margin

-4,770.71%

2026 Q2 · %

Exact inputs and evidence

Operating Income: -11402000 USD Source
Revenue: 239000 USD Source

Operating cash flow

-9.27 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -16907000 USD Source
Operating Cash Flow: -7639000 USD Source

Free cash flow

-10 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -16907000 USD Source
Operating Cash Flow: -7639000 USD Source
Capital Expenditure: 1392000 USD Source
Capital Expenditure: 613000 USD Source

Cash and cash equivalents: 17.8 million USD 2026-06-30 Source
Exact value

17800000 USD
Long-term debt including current maturities: 1.87 million U001 2017-12-31 Source
Exact value

1870000 U001
Shares outstanding: 32.6 million shares 2026-06-30 Source
Exact value

32622884 shares

Reported share-count change

14.00% · 4.01 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

28617046 shares · 2025-06-30· Source
32622884 shares · 2026-06-30· Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-08-10.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 6 of 11 periods available· newest 2025-12-31
Operating income: 9 of 11 periods available· newest 2025-12-31
Net income: 9 of 11 periods available· newest 2025-12-31
Operating cash flow: 9 of 11 periods available· newest 2025-12-31
Capital expenditure: 9 of 11 periods available· newest 2025-12-31
Total assets: 6 of 11 periods available· newest 2025-12-31
Total liabilities: 6 of 11 periods available· newest 2025-12-31
Current assets: 6 of 11 periods available· newest 2025-12-31
Current liabilities: 6 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 6 of 11 periods available· newest 2025-12-31
long term debt: No compatible figures in this window
Shares outstanding: 6 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+115.6%

Prior period

USD 1.88 million

2024-01-01 – 2024-12-31
Current period

USD 4.06 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

4055000 − 1881000 = 2174000 USD

1881000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
4055000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Insight Molecular Diagnostics Inc. · 2025-12-31 Insight Molecular Diagnostics Inc. (edgar:1642380) Year-over-year change in Revenue: 2174000 USD Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T19:30:20Z Snapshot: a5316f86360c0b47b6b9735e364ac2faffeace42269fe55b639a93150e928137 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1642380?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 4055000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1642380/000164238026000004/imdx-20251231.htm#3580780 Filing: 000164238026000004 Input fundies:Revenue: 1881000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1642380/000164238026000004/imdx-20251231.htm#3582592 Filing: 000164238026000004
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 10.44 million

Prior period

−USD 60.66 million

2024-01-01 – 2024-12-31
Current period

−USD 50.22 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-50222000 − -60663000 = 10441000 USD

-60663000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-50222000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Insight Molecular Diagnostics Inc. · 2025-12-31 Insight Molecular Diagnostics Inc. (edgar:1642380) Year-over-year change in Net income: 10441000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T19:30:20Z Snapshot: a5316f86360c0b47b6b9735e364ac2faffeace42269fe55b639a93150e928137 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1642380?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -50222000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1642380/000164238026000004/imdx-20251231.htm#3548626 Filing: 000164238026000004 Input fundies:NetIncome: -60663000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1642380/000164238026000004/imdx-20251231.htm#3550551 Filing: 000164238026000004
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 1.5 million

Prior period

−USD 20.69 million

2024-01-01 – 2024-12-31
Current period

−USD 22.18 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-22184000 − -20689000 = -1495000 USD

-20689000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-22184000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Insight Molecular Diagnostics Inc. · 2025-12-31 Insight Molecular Diagnostics Inc. (edgar:1642380) Year-over-year change in Operating cash flow: -1495000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T19:30:20Z Snapshot: a5316f86360c0b47b6b9735e364ac2faffeace42269fe55b639a93150e928137 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1642380?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -22184000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1642380/000164238026000004/imdx-20251231.htm#2155199 Filing: 000164238026000004 Input fundies:OperatingCashFlow: -20689000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1642380/000164238026000004/imdx-20251231.htm#2157089 Filing: 000164238026000004
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+517.2%

Prior period

USD 516,000

2024-01-01 – 2024-12-31
Current period

USD 3.19 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

3185000 − 516000 = 2669000 USD

516000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
3185000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Insight Molecular Diagnostics Inc. · 2025-12-31 Insight Molecular Diagnostics Inc. (edgar:1642380) Year-over-year change in Capital expenditure: 2669000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T19:30:20Z Snapshot: a5316f86360c0b47b6b9735e364ac2faffeace42269fe55b639a93150e928137 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1642380?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 3185000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1642380/000164238026000004/imdx-20251231.htm#2168268 Filing: 000164238026000004 Input fundies:CapitalExpenditure: 516000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1642380/000164238026000004/imdx-20251231.htm#2170044 Filing: 000164238026000004
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue USD 4.06 million 100% of revenue
Cost of revenue USD 1.75 million 43% of revenue
Operating expenses USD 53.42 million 1,317% of revenue
Operating income −USD 51.12 million −1,261% of revenue
Tax, interest and other Derived −USD 902,000 −22% of revenue
Net income −USD 50.22 million −1,239% of revenue

Cash

Operating cash flow −USD 22.18 million −547% of revenue
Capital expenditure USD 3.19 million 79% of revenue
Free cash flow Derived −USD 25.37 million −626% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2020 Operating loss: operating costs were 2,543% of revenue.
2021 Operating loss: operating costs were 2,544% of revenue.
2022 Operating loss: operating costs were 1,979% of revenue.
2023 Operating loss: operating costs were 1,772% of revenue.
2024 Operating loss: operating costs were 3,345% of revenue.
2025 Operating loss: operating costs were 1,361% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2020 2020-01-01 – 2020-12-31	1216000	30927000 Derived	-29711000	221000 Derived	-29932000	-27207000 Derived	Source 2020-01-01 – 2020-12-31: 1216000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -29711000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -29932000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -25980000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 1227000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	2198000	55923000 Derived	-53725000	10372000 Derived	-64097000	-38188000 Derived	Source 2021-01-01 – 2021-12-31: 2198000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -53725000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -64097000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -35941000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 2247000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	958000	18955000 Derived	-17997000	54905000 Derived	-72902000	-49908000 Derived	Source 2022-01-01 – 2022-12-31: 958000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -17997000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -72902000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -45568000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 4340000 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	1503000	26639000 Derived	-25136000	2645000 Derived	-27781000	-23606000 Derived	Source 2023-01-01 – 2023-12-31: 1503000 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -25136000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -27781000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -23325000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 281000 USD Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	1881000	62922000 Derived	-61041000	-378000 Derived	-60663000	-21205000 Derived	Source 2024-01-01 – 2024-12-31: 1881000 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -61041000 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -60663000 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: -20689000 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 516000 USD Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	4055000	55179000 Derived	-51124000	-902000 Derived	-50222000	-25369000 Derived	Source 2025-01-01 – 2025-12-31: 4055000 USD Inspect Revenue Open source 2025-01-01 – 2025-12-31: -51124000 USD Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -50222000 USD Inspect Net Income Open source 2025-01-01 – 2025-12-31: -22184000 USD Inspect Operating Cash Flow Open source 2025-01-01 – 2025-12-31: 3185000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 4.1M 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20202020-12-31	Revenue	1216000	Revenue: 1216000 Open source
20212021-12-31	Revenue	2198000	Revenue: 2198000 Open source
20222022-12-31	Revenue	958000	Revenue: 958000 Open source
20232023-12-31	Revenue	1503000	Revenue: 1503000 Open source
20242024-12-31	Revenue	1881000	Revenue: 1881000 Open source
20252025-12-31	Revenue	4055000	Revenue: 4055000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

115.6% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Year over year	No prior comparable period	Revenue: 1216000 Open source
20212021-12-31	Year over year	80.8%	Revenue: 2198000 Open source Revenue: 1216000 Open source
20222022-12-31	Year over year	-56.4%	Revenue: 958000 Open source Revenue: 2198000 Open source
20232023-12-31	Year over year	56.9%	Revenue: 1503000 Open source Revenue: 958000 Open source
20242024-12-31	Year over year	25.1%	Revenue: 1881000 Open source Revenue: 1503000 Open source
20252025-12-31	Year over year	115.6%	Revenue: 4055000 Open source Revenue: 1881000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -1,260.8% 2025

Net margin -1,238.5% 2025

Free cash flow margin -625.6% 2025

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Operating margin	-2,443.3%	Operating Income: -29711000 Open source Revenue: 1216000 Open source
20212021-12-31	Operating margin	-2,444.3%	Operating Income: -53725000 Open source Revenue: 2198000 Open source
20222022-12-31	Operating margin	-1,878.6%	Operating Income: -17997000 Open source Revenue: 958000 Open source
20232023-12-31	Operating margin	-1,672.4%	Operating Income: -25136000 Open source Revenue: 1503000 Open source
20242024-12-31	Operating margin	-3,245.1%	Operating Income: -61041000 Open source Revenue: 1881000 Open source
20252025-12-31	Operating margin	-1,260.8%	Operating Income: -51124000 Open source Revenue: 4055000 Open source
20202020-12-31	Net margin	-2,461.5%	Net Income: -29932000 Open source Revenue: 1216000 Open source
20212021-12-31	Net margin	-2,916.2%	Net Income: -64097000 Open source Revenue: 2198000 Open source
20222022-12-31	Net margin	-7,609.8%	Net Income: -72902000 Open source Revenue: 958000 Open source
20232023-12-31	Net margin	-1,848.4%	Net Income: -27781000 Open source Revenue: 1503000 Open source
20242024-12-31	Net margin	-3,225%	Net Income: -60663000 Open source Revenue: 1881000 Open source
20252025-12-31	Net margin	-1,238.5%	Net Income: -50222000 Open source Revenue: 4055000 Open source
20202020-12-31	Free cash flow margin	-2,237.4%	Revenue: 1216000 Open source Operating Cash Flow: -25980000 Open source Capital Expenditure: 1227000 Open source
20212021-12-31	Free cash flow margin	-1,737.4%	Revenue: 2198000 Open source Operating Cash Flow: -35941000 Open source Capital Expenditure: 2247000 Open source
20222022-12-31	Free cash flow margin	-5,209.6%	Revenue: 958000 Open source Operating Cash Flow: -45568000 Open source Capital Expenditure: 4340000 Open source
20232023-12-31	Free cash flow margin	-1,570.6%	Revenue: 1503000 Open source Operating Cash Flow: -23325000 Open source Capital Expenditure: 281000 Open source
20242024-12-31	Free cash flow margin	-1,127.3%	Revenue: 1881000 Open source Operating Cash Flow: -20689000 Open source Capital Expenditure: 516000 Open source
20252025-12-31	Free cash flow margin	-625.6%	Revenue: 4055000 Open source Operating Cash Flow: -22184000 Open source Capital Expenditure: 3185000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -22.2M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20202020-12-31	Operating cash flow	-25980000	Operating Cash Flow: -25980000 Open source
20212021-12-31	Operating cash flow	-35941000	Operating Cash Flow: -35941000 Open source
20222022-12-31	Operating cash flow	-45568000	Operating Cash Flow: -45568000 Open source
20232023-12-31	Operating cash flow	-23325000	Operating Cash Flow: -23325000 Open source
20242024-12-31	Operating cash flow	-20689000	Operating Cash Flow: -20689000 Open source
20252025-12-31	Operating cash flow	-22184000	Operating Cash Flow: -22184000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -25.4M 2025

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20202020-12-31	Free cash flow	-27207000	Operating Cash Flow: -25980000 Open source Capital Expenditure: 1227000 Open source
20212021-12-31	Free cash flow	-38188000	Operating Cash Flow: -35941000 Open source Capital Expenditure: 2247000 Open source
20222022-12-31	Free cash flow	-49908000	Operating Cash Flow: -45568000 Open source Capital Expenditure: 4340000 Open source
20232023-12-31	Free cash flow	-23606000	Operating Cash Flow: -23325000 Open source Capital Expenditure: 281000 Open source
20242024-12-31	Free cash flow	-21205000	Operating Cash Flow: -20689000 Open source Capital Expenditure: 516000 Open source
20252025-12-31	Free cash flow	-25369000	Operating Cash Flow: -22184000 Open source Capital Expenditure: 3185000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

222.2% 2025

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Liabilities / assets	39.6%	Total Liabilities: 21936000 Open source Total Assets: 55419000 Open source
20212021-12-31	Liabilities / assets	59.1%	Total Liabilities: 94346000 Open source Total Assets: 159563000 Open source
20222022-12-31	Liabilities / assets	60.4%	Total Liabilities: 60497000 Open source Total Assets: 100091000 Open source
20232023-12-31	Liabilities / assets	65.8%	Total Liabilities: 49298000 Open source Total Assets: 74892000 Open source
20242024-12-31	Liabilities / assets	135%	Total Liabilities: 47355000 Open source Total Assets: 35081000 Open source
20252025-12-31	Liabilities / assets	222.2%	Total Liabilities: 57220000 Open source Total Assets: 25756000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

1.27× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Current assets / current liabilities	1.03×	Current Assets: 9226000 Open source Current Liabilities: 8996000 Open source
20212021-12-31	Current assets / current liabilities	2.77×	Current Assets: 39143000 Open source Current Liabilities: 14120000 Open source
20222022-12-31	Current assets / current liabilities	2.11×	Current Assets: 25536000 Open source Current Liabilities: 12106000 Open source
20232023-12-31	Current assets / current liabilities	1.49×	Current Assets: 10698000 Open source Current Liabilities: 7194000 Open source
20242024-12-31	Current assets / current liabilities	1.62×	Current Assets: 11759000 Open source Current Liabilities: 7275000 Open source
20252025-12-31	Current assets / current liabilities	1.27×	Current Assets: 15306000 Open source Current Liabilities: 12075000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2017 2017-01-01 – 2017-12-31	−USD 19.38 million Exact value Exact value: -19375000 USD 2017-01-01 – 2017-12-31: -19375000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Insight Molecular Diagnostics Inc. · 2017-12-31 Insight Molecular Diagnostics Inc. (edgar:1642380) Net Income: -19375000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T19:30:20Z Snapshot: a5316f86360c0b47b6b9735e364ac2faffeace42269fe55b639a93150e928137 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1642380/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -19375000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1642380/000149315219004549/ocx-20181231.xml#89165 Filing: 000149315219004549 The citation records this snapshot. The page link may show a newer release later.	−USD 13.39 million Exact value Exact value: -13385000 USD 2017-01-01 – 2017-12-31: -13385000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Insight Molecular Diagnostics Inc. · 2017-12-31 Insight Molecular Diagnostics Inc. (edgar:1642380) Operating Cash Flow: -13385000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T19:30:20Z Snapshot: a5316f86360c0b47b6b9735e364ac2faffeace42269fe55b639a93150e928137 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1642380/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -13385000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1642380/000149315219004549/ocx-20181231.xml#95544 Filing: 000149315219004549 The citation records this snapshot. The page link may show a newer release later.	USD 91,000 Exact value Exact value: 91000 USD 2017-01-01 – 2017-12-31: 91000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Insight Molecular Diagnostics Inc. · 2017-12-31 Insight Molecular Diagnostics Inc. (edgar:1642380) Capital Expenditure: 91000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T19:30:20Z Snapshot: a5316f86360c0b47b6b9735e364ac2faffeace42269fe55b639a93150e928137 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1642380/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 91000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1642380/000149315219004549/ocx-20181231.xml#96236 Filing: 000149315219004549 The citation records this snapshot. The page link may show a newer release later.	−USD 13.48 million Calculation and evidence -13385000 − 91000 USD Exact free cash flow: -13476000 USD 2017-01-01 – 2017-12-31: -13385000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 91000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Insight Molecular Diagnostics Inc. · 2017-12-31 Insight Molecular Diagnostics Inc. (edgar:1642380) Free cash flow: -13476000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T19:30:20Z Snapshot: a5316f86360c0b47b6b9735e364ac2faffeace42269fe55b639a93150e928137 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1642380?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -13385000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1642380/000149315219004549/ocx-20181231.xml#95544 Filing: 000149315219004549 Input fundies:CapitalExpenditure: 91000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1642380/000149315219004549/ocx-20181231.xml#96236 Filing: 000149315219004549 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 15.75 million Exact value Exact value: -15754000 USD 2018-01-01 – 2018-12-31: -15754000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Insight Molecular Diagnostics Inc. · 2018-12-31 Insight Molecular Diagnostics Inc. (edgar:1642380) Net Income: -15754000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T19:30:20Z Snapshot: a5316f86360c0b47b6b9735e364ac2faffeace42269fe55b639a93150e928137 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1642380/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -15754000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1642380/000149315220004738/ocx-20191231.xml#569676 Filing: 000149315220004738 The citation records this snapshot. The page link may show a newer release later.	−USD 11.65 million Exact value Exact value: -11649000 USD 2018-01-01 – 2018-12-31: -11649000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Insight Molecular Diagnostics Inc. · 2018-12-31 Insight Molecular Diagnostics Inc. (edgar:1642380) Operating Cash Flow: -11649000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T19:30:20Z Snapshot: a5316f86360c0b47b6b9735e364ac2faffeace42269fe55b639a93150e928137 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1642380/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -11649000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1642380/000149315220004738/ocx-20191231.xml#591976 Filing: 000149315220004738 The citation records this snapshot. The page link may show a newer release later.	USD 31,000 Exact value Exact value: 31000 USD 2018-01-01 – 2018-12-31: 31000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Insight Molecular Diagnostics Inc. · 2018-12-31 Insight Molecular Diagnostics Inc. (edgar:1642380) Capital Expenditure: 31000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T19:30:20Z Snapshot: a5316f86360c0b47b6b9735e364ac2faffeace42269fe55b639a93150e928137 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1642380/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 31000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1642380/000149315220004738/ocx-20191231.xml#592655 Filing: 000149315220004738 The citation records this snapshot. The page link may show a newer release later.	−USD 11.68 million Calculation and evidence -11649000 − 31000 USD Exact free cash flow: -11680000 USD 2018-01-01 – 2018-12-31: -11649000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 31000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Insight Molecular Diagnostics Inc. · 2018-12-31 Insight Molecular Diagnostics Inc. (edgar:1642380) Free cash flow: -11680000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T19:30:20Z Snapshot: a5316f86360c0b47b6b9735e364ac2faffeace42269fe55b639a93150e928137 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1642380?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -11649000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1642380/000149315220004738/ocx-20191231.xml#591976 Filing: 000149315220004738 Input fundies:CapitalExpenditure: 31000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1642380/000149315220004738/ocx-20191231.xml#592655 Filing: 000149315220004738 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 22.43 million Exact value Exact value: -22426000 USD 2019-01-01 – 2019-12-31: -22426000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Insight Molecular Diagnostics Inc. · 2019-12-31 Insight Molecular Diagnostics Inc. (edgar:1642380) Net Income: -22426000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T19:30:20Z Snapshot: a5316f86360c0b47b6b9735e364ac2faffeace42269fe55b639a93150e928137 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1642380/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -22426000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1642380/000149315221006465/ocx-20201231.xml#146400 Filing: 000149315221006465 The citation records this snapshot. The page link may show a newer release later.	−USD 19.72 million Exact value Exact value: -19715000 USD 2019-01-01 – 2019-12-31: -19715000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Insight Molecular Diagnostics Inc. · 2019-12-31 Insight Molecular Diagnostics Inc. (edgar:1642380) Operating Cash Flow: -19715000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T19:30:20Z Snapshot: a5316f86360c0b47b6b9735e364ac2faffeace42269fe55b639a93150e928137 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1642380/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -19715000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1642380/000149315221006465/ocx-20201231.xml#154992 Filing: 000149315221006465 The citation records this snapshot. The page link may show a newer release later.	USD 918,000 Exact value Exact value: 918000 USD 2019-01-01 – 2019-12-31: 918000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Insight Molecular Diagnostics Inc. · 2019-12-31 Insight Molecular Diagnostics Inc. (edgar:1642380) Capital Expenditure: 918000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T19:30:20Z Snapshot: a5316f86360c0b47b6b9735e364ac2faffeace42269fe55b639a93150e928137 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1642380/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 918000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1642380/000149315221006465/ocx-20201231.xml#155364 Filing: 000149315221006465 The citation records this snapshot. The page link may show a newer release later.	−USD 20.63 million Calculation and evidence -19715000 − 918000 USD Exact free cash flow: -20633000 USD 2019-01-01 – 2019-12-31: -19715000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 918000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Insight Molecular Diagnostics Inc. · 2019-12-31 Insight Molecular Diagnostics Inc. (edgar:1642380) Free cash flow: -20633000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T19:30:20Z Snapshot: a5316f86360c0b47b6b9735e364ac2faffeace42269fe55b639a93150e928137 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1642380?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -19715000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1642380/000149315221006465/ocx-20201231.xml#154992 Filing: 000149315221006465 Input fundies:CapitalExpenditure: 918000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1642380/000149315221006465/ocx-20201231.xml#155364 Filing: 000149315221006465 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 29.93 million Exact value Exact value: -29932000 USD 2020-01-01 – 2020-12-31: -29932000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Insight Molecular Diagnostics Inc. · 2020-12-31 Insight Molecular Diagnostics Inc. (edgar:1642380) Net Income: -29932000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T19:30:20Z Snapshot: a5316f86360c0b47b6b9735e364ac2faffeace42269fe55b639a93150e928137 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1642380/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -29932000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1642380/000149315222006677/form10-k.htm#1188194 Filing: 000149315222006677 The citation records this snapshot. The page link may show a newer release later.	−USD 25.98 million Exact value Exact value: -25980000 USD 2020-01-01 – 2020-12-31: -25980000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Insight Molecular Diagnostics Inc. · 2020-12-31 Insight Molecular Diagnostics Inc. (edgar:1642380) Operating Cash Flow: -25980000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T19:30:20Z Snapshot: a5316f86360c0b47b6b9735e364ac2faffeace42269fe55b639a93150e928137 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1642380/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -25980000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1642380/000149315222006677/form10-k.htm#1204626 Filing: 000149315222006677 The citation records this snapshot. The page link may show a newer release later.	USD 1.23 million Exact value Exact value: 1227000 USD 2020-01-01 – 2020-12-31: 1227000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Insight Molecular Diagnostics Inc. · 2020-12-31 Insight Molecular Diagnostics Inc. (edgar:1642380) Capital Expenditure: 1227000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T19:30:20Z Snapshot: a5316f86360c0b47b6b9735e364ac2faffeace42269fe55b639a93150e928137 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1642380/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1227000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1642380/000149315222006677/form10-k.htm#1210003 Filing: 000149315222006677 The citation records this snapshot. The page link may show a newer release later.	−USD 27.21 million Calculation and evidence -25980000 − 1227000 USD Exact free cash flow: -27207000 USD 2020-01-01 – 2020-12-31: -25980000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 1227000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Insight Molecular Diagnostics Inc. · 2020-12-31 Insight Molecular Diagnostics Inc. (edgar:1642380) Free cash flow: -27207000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T19:30:20Z Snapshot: a5316f86360c0b47b6b9735e364ac2faffeace42269fe55b639a93150e928137 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1642380?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -25980000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1642380/000149315222006677/form10-k.htm#1204626 Filing: 000149315222006677 Input fundies:CapitalExpenditure: 1227000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1642380/000149315222006677/form10-k.htm#1210003 Filing: 000149315222006677 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 64.1 million Exact value Exact value: -64097000 USD 2021-01-01 – 2021-12-31: -64097000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Insight Molecular Diagnostics Inc. · 2021-12-31 Insight Molecular Diagnostics Inc. (edgar:1642380) Net Income: -64097000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T19:30:20Z Snapshot: a5316f86360c0b47b6b9735e364ac2faffeace42269fe55b639a93150e928137 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1642380/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -64097000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1642380/000149315223012005/form10-k.htm#1199490 Filing: 000149315223012005 The citation records this snapshot. The page link may show a newer release later.	−USD 35.94 million Exact value Exact value: -35941000 USD 2021-01-01 – 2021-12-31: -35941000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Insight Molecular Diagnostics Inc. · 2021-12-31 Insight Molecular Diagnostics Inc. (edgar:1642380) Operating Cash Flow: -35941000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T19:30:20Z Snapshot: a5316f86360c0b47b6b9735e364ac2faffeace42269fe55b639a93150e928137 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1642380/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -35941000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1642380/000149315223012005/form10-k.htm#1216731 Filing: 000149315223012005 The citation records this snapshot. The page link may show a newer release later.	USD 2.25 million Exact value Exact value: 2247000 USD 2021-01-01 – 2021-12-31: 2247000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Insight Molecular Diagnostics Inc. · 2021-12-31 Insight Molecular Diagnostics Inc. (edgar:1642380) Capital Expenditure: 2247000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T19:30:20Z Snapshot: a5316f86360c0b47b6b9735e364ac2faffeace42269fe55b639a93150e928137 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1642380/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2247000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1642380/000149315223012005/form10-k.htm#1221290 Filing: 000149315223012005 The citation records this snapshot. The page link may show a newer release later.	−USD 38.19 million Calculation and evidence -35941000 − 2247000 USD Exact free cash flow: -38188000 USD 2021-01-01 – 2021-12-31: -35941000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 2247000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Insight Molecular Diagnostics Inc. · 2021-12-31 Insight Molecular Diagnostics Inc. (edgar:1642380) Free cash flow: -38188000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T19:30:20Z Snapshot: a5316f86360c0b47b6b9735e364ac2faffeace42269fe55b639a93150e928137 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1642380?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -35941000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1642380/000149315223012005/form10-k.htm#1216731 Filing: 000149315223012005 Input fundies:CapitalExpenditure: 2247000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1642380/000149315223012005/form10-k.htm#1221290 Filing: 000149315223012005 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 72.9 million Exact value Exact value: -72902000 USD 2022-01-01 – 2022-12-31: -72902000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Insight Molecular Diagnostics Inc. · 2022-12-31 Insight Molecular Diagnostics Inc. (edgar:1642380) Net Income: -72902000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T19:30:20Z Snapshot: a5316f86360c0b47b6b9735e364ac2faffeace42269fe55b639a93150e928137 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1642380/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -72902000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1642380/000149315224014720/form10-k.htm#1429389 Filing: 000149315224014720 The citation records this snapshot. The page link may show a newer release later.	−USD 45.57 million Exact value Exact value: -45568000 USD 2022-01-01 – 2022-12-31: -45568000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Insight Molecular Diagnostics Inc. · 2022-12-31 Insight Molecular Diagnostics Inc. (edgar:1642380) Operating Cash Flow: -45568000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T19:30:20Z Snapshot: a5316f86360c0b47b6b9735e364ac2faffeace42269fe55b639a93150e928137 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1642380/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -45568000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1642380/000149315224014720/form10-k.htm#1184629 Filing: 000149315224014720 The citation records this snapshot. The page link may show a newer release later.	USD 4.34 million Exact value Exact value: 4340000 USD 2022-01-01 – 2022-12-31: 4340000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Insight Molecular Diagnostics Inc. · 2022-12-31 Insight Molecular Diagnostics Inc. (edgar:1642380) Capital Expenditure: 4340000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T19:30:20Z Snapshot: a5316f86360c0b47b6b9735e364ac2faffeace42269fe55b639a93150e928137 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1642380/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 4340000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1642380/000149315224014720/form10-k.htm#1188184 Filing: 000149315224014720 The citation records this snapshot. The page link may show a newer release later.	−USD 49.91 million Calculation and evidence -45568000 − 4340000 USD Exact free cash flow: -49908000 USD 2022-01-01 – 2022-12-31: -45568000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 4340000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Insight Molecular Diagnostics Inc. · 2022-12-31 Insight Molecular Diagnostics Inc. (edgar:1642380) Free cash flow: -49908000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T19:30:20Z Snapshot: a5316f86360c0b47b6b9735e364ac2faffeace42269fe55b639a93150e928137 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1642380?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -45568000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1642380/000149315224014720/form10-k.htm#1184629 Filing: 000149315224014720 Input fundies:CapitalExpenditure: 4340000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1642380/000149315224014720/form10-k.htm#1188184 Filing: 000149315224014720 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 27.78 million Exact value Exact value: -27781000 USD 2023-01-01 – 2023-12-31: -27781000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Insight Molecular Diagnostics Inc. · 2023-12-31 Insight Molecular Diagnostics Inc. (edgar:1642380) Net Income: -27781000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T19:30:20Z Snapshot: a5316f86360c0b47b6b9735e364ac2faffeace42269fe55b639a93150e928137 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1642380/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -27781000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1642380/000095017025043852/ocx-20241231.htm#4090681 Filing: 000095017025043852 The citation records this snapshot. The page link may show a newer release later.	−USD 23.33 million Exact value Exact value: -23325000 USD 2023-01-01 – 2023-12-31: -23325000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Insight Molecular Diagnostics Inc. · 2023-12-31 Insight Molecular Diagnostics Inc. (edgar:1642380) Operating Cash Flow: -23325000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T19:30:20Z Snapshot: a5316f86360c0b47b6b9735e364ac2faffeace42269fe55b639a93150e928137 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1642380/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -23325000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1642380/000095017025043852/ocx-20241231.htm#2769629 Filing: 000095017025043852 The citation records this snapshot. The page link may show a newer release later.	USD 281,000 Exact value Exact value: 281000 USD 2023-01-01 – 2023-12-31: 281000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Insight Molecular Diagnostics Inc. · 2023-12-31 Insight Molecular Diagnostics Inc. (edgar:1642380) Capital Expenditure: 281000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T19:30:20Z Snapshot: a5316f86360c0b47b6b9735e364ac2faffeace42269fe55b639a93150e928137 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1642380/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 281000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1642380/000095017025043852/ocx-20241231.htm#2785258 Filing: 000095017025043852 The citation records this snapshot. The page link may show a newer release later.	−USD 23.61 million Calculation and evidence -23325000 − 281000 USD Exact free cash flow: -23606000 USD 2023-01-01 – 2023-12-31: -23325000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 281000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Insight Molecular Diagnostics Inc. · 2023-12-31 Insight Molecular Diagnostics Inc. (edgar:1642380) Free cash flow: -23606000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T19:30:20Z Snapshot: a5316f86360c0b47b6b9735e364ac2faffeace42269fe55b639a93150e928137 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1642380?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -23325000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1642380/000095017025043852/ocx-20241231.htm#2769629 Filing: 000095017025043852 Input fundies:CapitalExpenditure: 281000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1642380/000095017025043852/ocx-20241231.htm#2785258 Filing: 000095017025043852 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 60.66 million Exact value Exact value: -60663000 USD 2024-01-01 – 2024-12-31: -60663000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Insight Molecular Diagnostics Inc. · 2024-12-31 Insight Molecular Diagnostics Inc. (edgar:1642380) Net Income: -60663000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T19:30:20Z Snapshot: a5316f86360c0b47b6b9735e364ac2faffeace42269fe55b639a93150e928137 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1642380/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -60663000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1642380/000164238026000004/imdx-20251231.htm#3550551 Filing: 000164238026000004 The citation records this snapshot. The page link may show a newer release later.	−USD 20.69 million Exact value Exact value: -20689000 USD 2024-01-01 – 2024-12-31: -20689000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Insight Molecular Diagnostics Inc. · 2024-12-31 Insight Molecular Diagnostics Inc. (edgar:1642380) Operating Cash Flow: -20689000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T19:30:20Z Snapshot: a5316f86360c0b47b6b9735e364ac2faffeace42269fe55b639a93150e928137 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1642380/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -20689000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1642380/000164238026000004/imdx-20251231.htm#2157089 Filing: 000164238026000004 The citation records this snapshot. The page link may show a newer release later.	USD 516,000 Exact value Exact value: 516000 USD 2024-01-01 – 2024-12-31: 516000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Insight Molecular Diagnostics Inc. · 2024-12-31 Insight Molecular Diagnostics Inc. (edgar:1642380) Capital Expenditure: 516000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T19:30:20Z Snapshot: a5316f86360c0b47b6b9735e364ac2faffeace42269fe55b639a93150e928137 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1642380/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 516000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1642380/000164238026000004/imdx-20251231.htm#2170044 Filing: 000164238026000004 The citation records this snapshot. The page link may show a newer release later.	−USD 21.21 million Calculation and evidence -20689000 − 516000 USD Exact free cash flow: -21205000 USD 2024-01-01 – 2024-12-31: -20689000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 516000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Insight Molecular Diagnostics Inc. · 2024-12-31 Insight Molecular Diagnostics Inc. (edgar:1642380) Free cash flow: -21205000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T19:30:20Z Snapshot: a5316f86360c0b47b6b9735e364ac2faffeace42269fe55b639a93150e928137 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1642380?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -20689000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1642380/000164238026000004/imdx-20251231.htm#2157089 Filing: 000164238026000004 Input fundies:CapitalExpenditure: 516000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1642380/000164238026000004/imdx-20251231.htm#2170044 Filing: 000164238026000004 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 50.22 million Exact value Exact value: -50222000 USD 2025-01-01 – 2025-12-31: -50222000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Insight Molecular Diagnostics Inc. · 2025-12-31 Insight Molecular Diagnostics Inc. (edgar:1642380) Net Income: -50222000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T19:30:20Z Snapshot: a5316f86360c0b47b6b9735e364ac2faffeace42269fe55b639a93150e928137 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1642380/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -50222000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1642380/000164238026000004/imdx-20251231.htm#3548626 Filing: 000164238026000004 The citation records this snapshot. The page link may show a newer release later.	−USD 22.18 million Exact value Exact value: -22184000 USD 2025-01-01 – 2025-12-31: -22184000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Insight Molecular Diagnostics Inc. · 2025-12-31 Insight Molecular Diagnostics Inc. (edgar:1642380) Operating Cash Flow: -22184000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T19:30:20Z Snapshot: a5316f86360c0b47b6b9735e364ac2faffeace42269fe55b639a93150e928137 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1642380/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -22184000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1642380/000164238026000004/imdx-20251231.htm#2155199 Filing: 000164238026000004 The citation records this snapshot. The page link may show a newer release later.	USD 3.19 million Exact value Exact value: 3185000 USD 2025-01-01 – 2025-12-31: 3185000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Insight Molecular Diagnostics Inc. · 2025-12-31 Insight Molecular Diagnostics Inc. (edgar:1642380) Capital Expenditure: 3185000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T19:30:20Z Snapshot: a5316f86360c0b47b6b9735e364ac2faffeace42269fe55b639a93150e928137 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1642380/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3185000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1642380/000164238026000004/imdx-20251231.htm#2168268 Filing: 000164238026000004 The citation records this snapshot. The page link may show a newer release later.	−USD 25.37 million Calculation and evidence -22184000 − 3185000 USD Exact free cash flow: -25369000 USD 2025-01-01 – 2025-12-31: -22184000 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 3185000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Insight Molecular Diagnostics Inc. · 2025-12-31 Insight Molecular Diagnostics Inc. (edgar:1642380) Free cash flow: -25369000 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T19:30:20Z Snapshot: a5316f86360c0b47b6b9735e364ac2faffeace42269fe55b639a93150e928137 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1642380?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -22184000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1642380/000164238026000004/imdx-20251231.htm#2155199 Filing: 000164238026000004 Input fundies:CapitalExpenditure: 3185000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1642380/000164238026000004/imdx-20251231.htm#2168268 Filing: 000164238026000004 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

64 filings · 3,036 latest values · 3,036 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001642380, 1642380, IMDX, OCX, edgar:1642380

Also known as Insight Molecular Diagnostics Inc., OncoCyte Corp, Oncocyte Corporation, Oncocyte Corp, Oncocyte Corporation

Insight Molecular Diagnostics Inc.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation